Total revenue of $12 million; Diluted Earnings Per Share (EPS) of $0.06; Both in line with fiscal 2023 guidance and Q1 expectations for revenue seasonality shift.
Provides capital allocation strategy update focusing on corporate development activities, $50 million share repurchase program, and internal investment
Conference call to be on Wednesday, January 4, 2023, at 5 p.m. EST
Project will focus on the development of a modeling & simulation framework to support an assessment of bioequivalence for locally-acting drugs in the gastrointestinal tract
Ex-Anvisa General Manager will contribute to global regulatory strategies involving pharmacometrics
International organization’s mission is to close the gender gap in technology
Collaboration combines novel in vitro experimental methods and mechanistic modeling to accelerate development of orally inhaled drug products (OIDPs) and propose alternative approaches for bioequivalence
Fiscal 2022 revenue increased 16% year-over-year to $53.9 million
Diluted earnings per share increased 28% year-over-year to $0.60
Provides Fiscal 2023 guidance for total revenue of $59.3 million to $62.0 million (+10% to 15%)
Board of Directors announces quarterly dividend of $0.06 per share
New update expands the library of virtual populations and enhances connections between software platforms
Chief executive officer Shawn O’Connor will be presenting at the Sidoti Fall Small Cap Investor Conference taking place virtually on September 21-22, 2022.
Management will be presenting at Baird’s 2022 Global Healthcare Conference
ILDsym will enable new software and services revenue by aiding development of therapies for the treatment of patients with ILD as a complication of systemic sclerosis
Extensive data sharing with large pharmaceutical partner will expand property prediction space and improve model performance
Several posters and oral presentations involved the use of MonolixSuite®
Tenured employees support St. Jude in finding cures and saving children
Total revenue growth of 17%; Software revenue growth of 16%; Services revenue growth of 19%;
Diluted Earnings Per Share (EPS) growth of 11%;
Board of Directors announces quarterly dividend of $0.06 per share
Record-setting attendance for the global pharmacometrics community
Simulations Plus' Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to support the development of a candidate COVID-19 therapy.
Conference call to be on Wednesday, July 6, 2022, at 5:00 PM ET
DILIsym application contributes to approval of new drugs for migraine treatment
